A Randomized, Placebo-Controlled, Dose-Escalation Study to Determine the Safety, Tolerability, and Immunogenicity of an HPV-16 Therapeutic Vaccine in HIV-Positive Participants With Oncogenic HPV Infection of the Anus
Authors:
- Jonathan S AndersonJAJonathan S Anderson
- Jennifer HoyJHJennifer Hoy
- Richard HillmanRHRichard Hillman
- Megan BarndenMBMegan Barnden
- Beng EuBEBeng Eu
- Andrew McKenzieAMAndrew McKenzie
- Charmaine GittlesonCGCharmaine Gittleson
- 1 November 2009
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 52 (3) , 371-381
Abstract
Study aimed to assess safety, tolerability, and immunogenicity of novel therapeutic HPV-16 E6E7 ISCOMATRIX vaccine for treatment of human papilloma virus (HPV)-related anal intraepithelial neoplasia in HIV-infected men who have sex with men with moderate immunosuppression. Randomized, multicenter, blinded, placebo-controlled, dose-escalating study investigating 3 different doses of vaccine and different dose schedule. Primary objective to determine safety and tolerability, including clinical status, maintenance of virological control, and CD4 cell count for more than 252 days. Thirty-five men who have sex with men enrolled; median age 47 years; current CD4 count 627 cells per milliliter; nadir CD4 count 154 cells per milliliter; 94% current antiretrovirals; 100% high-risk HPV types; 69% abnormal anal cytology; and 34% anal intraepithelial neoplasia 1-3 on high-resolution anoscopy. No dose-limiting toxicities or serious adverse events in HPV-16 vaccine recipients. Most HPV-16 vaccine recipients reported moderate/severe short-term injection site reactions and systemic reactions including headache, myalgia, and fatigue. CD4 cell counts remained stable. Five participants had transiently detectable viral loads. Ninety-six percent of vaccine recipients had at least a 4-fold increase in HPV-16 antibody from prevaccination levels. Seventy-one percent had at least a 3-fold increase in interferon-gamma responses to E6E7 peptides. The novel therapeutic HPV-16 E6E7 ISCOMATRIX vaccine seemed safe and reasonably well tolerated. The therapeutic vaccine induces strong and durable antibody responses and moderate interferon-gamma levels that fell to prevaccination levels by week 24.Keywords
This publication has 37 references indexed in Scilit:
- Abnormal anal cytology in high-risk human papilloma virus infection in HIV-infected AustraliansSexually Transmitted Infections, 2008
- Vaccination of Healthy Volunteers with Human Papillomavirus Type 16 L2E7E6 Fusion Protein Induces Serum Antibody that Neutralizes across Papillomavirus SpeciesCancer Research, 2006
- HIV/AIDS: Screening HIV‐Infected Individuals for Anal Cancer Precursor Lesions: A Systematic ReviewClinical Infectious Diseases, 2006
- Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975–2002British Journal of Cancer, 2006
- Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trialInternational Journal of Gynecological Cancer, 2006
- The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinicSexually Transmitted Infections, 2005
- Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX? adjuvant in women with cervical intraepithelial neoplasiaVaccine, 2004
- Is screening for anal cancer warranted in homosexual men?Sexual Health, 2004
- ISCOMATRIX™ adjuvant: an adjuvant suitable for use in anticancer vaccinesVaccine, 2004
- Lack of response of anal intra-epithelial neoplasia to highly active antiretroviral therapyAIDS, 2003